Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction

Completed

• Conditions: Glucagon-like Peptide-1; Complications; STEMI - ST Elevation Myocardial Infarction; Bleeding

• Registration Number: NCT03314844
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

Glucagon-like peptide-1 (GLP-1), produced mainly in enteroendocrine cells, participates in energy homeostasis and glucose metabolism by regulating islet hormone secretion, gastrointestinal motility, and food intake, making GLP-1 agonist a treatment for diabetes and obesity. Pre-clinical and clinical studies have demonstrated that GLP-1 also has cardio-protection effects. GLP-1 agonists is able to improve markers of cardiac function, reduce myocardial infarct size and post-myocardial infarction remodeling in experimental myocardial infarction. And GLP-1 infusion improved left ventricular function and increases myocardial salvage in patients with acute myocardial infarction (AMI). The investigators' previous study found that GLP-1 analogues attenuated ischemia-reperfusion induced apoptosis of stem- and myocardial microvascular endothelial cells, and liraglutide (a GLP-1 analog) usage during hospital stay can prevent no-reflow and improve heart function in AMI. Therefore, the investigators carried out a cohort study to evaluate the association between plasma GLP-1 and in-hospital complications in patients with ST-segment elevation myocardial infarction.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02-01
• Primary Completion: 2015-02-01
• Study Completion: 2015-02-01
• Status Verified: 2017-10
• Study First Submitted: 2017-10-16
• Study First Submitted QC: 2017-10-16
• Study First Posted: 2017-10-19
• Last Update Submitted: 2017-10-19
• Last Update Posted: 2017-10-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 564

Inclusion Criteria

• a diagnosis of STEMI and needed PCI

Exclusion Criteria

• patients with cancer patients who used DPP4 inhibitor patients who used GLP1 analogue

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
in-hospital complications	Time Frame: up to 2 week after PCI (until discharge)	defined as acute heart failure, atrial fibrillation, chest pain or re-acute myocardial infarction, complete atrioventricular block, cerebrovascular disease, ventricular fibrillation or ventricular tachycardia

Secondary Outcome Measures

Name	Time	Method
in-hospital major bleeding	Time Frame: up to 2 week after PCI (until discharge)	defined as absolute hemoglobin drop (baseline to nadir)≥4g/dl, intracranial hemorrhage, retroperitoneal hemorrhage, use of red blood cell transfusion in patients with a baseline hemoglobin ≥9.0 g/dl, and use of red blood cell transfusion among patients with a baseline hemoglobin \<9.0 g/dl and a witnessed bleeding event
in-hospital major adverse cardiac or cerebrovascular events	Time Frame: up to 2 week after PCI (until discharge)]	the composite of death, nonfatal MI, or stroke